Target intelligence / Profile preview

Ceramide synthase 3 (CerS3)

Target
CerS3
Molecular classification
Enzyme, Sphingosine N-acyltransferase, Membrane protein
01

Overview

Ceramide synthase 3 (CerS3) is an integral membrane enzyme of the endoplasmic reticulum that catalyzes the N-acylation of sphinganine or sphingosine to generate ultra-long-chain ceramides, particularly those with acyl chains longer than C24. CerS3 is highly expressed in skin and testis. In skin, it is essential for producing specialized ceramides that form the lipid barrier of the stratum corneum, crucial for preventing water loss and environmental penetration. In testis, CerS3 is required for the generation of glycosphingolipids involved in spermatogenesis and hormone production. Mutations in the CERS3 gene cause congenital autosomal recessive ichthyosis and are linked to male infertility. CerS3 has not yet been the subject of direct therapeutic interventions, but the broader ceramide biosynthetic pathway has emerged as a target in metabolic, inflammatory, and neoplastic disorders[1][2][3][4].

Other names
CERS3LASS3ARCI9longevity assurance homologue 3
02

Mechanism of action

Inhibition of sphingosine N-acyltransferase activity (blocking ceramide synthesis) Modulation of sphingolipid metabolism[2][7]

03

Biological functions

Sphingolipid biosynthesisEpidermal barrier formationKeratinocyte differentiationSperm formation (spermatogenesis)Androgen production
04

Disease associations

Skin disorder (autosomal recessive congenital ichthyosis)Male infertilityPotential roles in metabolic diseases and cancer (as extrapolated from ceramide pathway’s involvement in these conditions)
05

Safety considerations

Potential disruption of epidermal barrier function (leading to skin dehydration and ichthyosis)Possible effects on spermatogenesis and fertilityGlobal inhibition of ceramide synthases may perturb multiple cellular processes due to central role in sphingolipid metabolism[3]
06

Interacting drugs

No clinically approved drugs directly target CerS3 as of current knowledge; experimental tool compounds (like FTY720 and mycotoxins such as fumonisin B1) inhibit ceramide synthases in general but with varying isoform selectivity[2][7].
07

Biomarkers

Mutations in CERS3 gene (for screening congenital ichthyosis and male infertility)Levels of ultra-long-chain ceramides in skin (for epidermal barrier integrity)

Beyond the preview

Go deeper on Ceramide synthase 3 (CerS3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceramide synthase 3 (CerS3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call